Associations Between Changes in Plasma Renin Activity and Aldosterone Concentrations and Changes in Kidney Function After Treatment for Primary Aldosteronism-Reference-Cited by-同舟云学术

Associations Between Changes in Plasma Renin Activity and Aldosterone Concentrations and Changes in Kidney Function After Treatment for Primary Aldosteronism

Published:2020-08 Issue:8 Volume:5 Page:1291-1297
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Kobayashi Yusuke,Haze Tatsuya,Yano Yuichiro,Tamura Kouichi,Kurihara Isao,Ichijo Takamasa,Yoneda Takashi,Katabami Takuyuki,Tsuiki Mika,Wada Norio,Ogawa Yoshihiro,Kawashima Junji,Sone Masakatsu,Inagaki Nobuya,Yamada Tetsuya,Okamoto Ryuji,Fujita Megumi,Kamemura Kohei,Yamamoto Koichi,Izawa Shoichiro,Tanabe Akiyo,Naruse Mitsuhide

Funder

National Center for Global Health and Medicine

Japan Agency for Medical Research and Development

Publisher

Elsevier BV

Subject

Nephrology

Reference34 articles.

1. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis;Käyser;J Clin Endocrinol Metab,2016

2. Renal damage in primary aldosteronism: results of the PAPY Study;Rossi;Hypertension,2006

3. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats;Blasi;Kidney Int,2003

4. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1;Shibata;Hypertension,2007

5. Long-term renal outcomes in patients with primary aldosteronism;Sechi;JAMA,2006

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary Aldosteronism and Kidney Hemodynamics: Adding Another Piece to the Puzzle;American Journal of Hypertension;2024-06-27

2. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study;Advances in Therapy;2024-02-04

3. Exploratory study on the relationship between urinary sodium/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study;Hypertension Research;2024-01-11

4. Comparisons of risk factors for post-treatment renal dysfunction between the two major subtypes of primary aldosteronism;Endocrine;2023-12-12

5. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH);Advances in Therapy;2023-09-21